Literature DB >> 2450250

Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog.

J D Kohli1, D Glock, L I Goldberg.   

Abstract

Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activities of fenoldopam were determined in pentobarbital anesthetized dogs. The renal vasodilating effect of intravenous infusions of fenoldopam was used as an index of its DA1-agonist activity. Inhibition by fenoldopam of femoral vasoconstriction produced by intraarterial administration of phenylephrine (a relatively selective alpha 1 agonist) and UK 14,304 ( a relatively selective alpha 2 agonist) was used to determine its alpha-adrenoceptor antagonist activity. Intravenous infusions of 0.1 and 0.2 microgram/kg/min of fenoldopam caused dose-related reductions in renal vascular resistance and mean arterial pressure. Higher rates of infusions of fenoldopam (2 and 5 micrograms/kg/min) were given after pretreatment with 50 micrograms/kg/min SCH 23390 (a DA1-selective antagonist) to attenuate DA1-mediated hemodynamic effects. After SCH 23390, the infusion of 5 micrograms/kg/min of fenoldopam produced approximately the same hypotensive and renal vasodilating actions as the 0.2 microgram/kg/min infusion without SCH 23390. Alpha-adrenoceptor blocking activity was not observed with the 0.1, 0.2, and 2 micrograms/kg/min infusions of fenoldopam. The 5 micrograms/kg/min infusion, however, produced 14 and 25% inhibition of the vasoconstrictor effects of phenylephrine and UK 14,304, respectively. These data indicate that fenoldopam decreases renal vascular resistance in doses which are 25 to 50 times less than the dose needed to antagonize alpha adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450250     DOI: 10.1097/00005344-198801000-00018

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist.

Authors:  S S Ng; C C Pang
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 2.  Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies.

Authors:  R N Brogden; A Markham
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

3.  The effects of quinpirole and fenoldopam on the potassium-evoked overflow of endogenous dopamine and noradrenaline in dog mesenteric arteries.

Authors:  P Soares-da-Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.